In cancers, including TNBC, STAT3 is constitutively activated and frequently associated with poor prognosis and tumor resistance to anticancer therapy (Banerjee and Resat, 2015; D'Anello et al., 2010; Marotta et al., 2011; Real et al., 2002; Wei et al., 2014). This evidence concerns the gene STAT3 and cancer.